Clinic 1 Methadone Clinic

Clinic 1 Methadone Clinic (New York, NY) is a SAMHSA Behavioral Health Treatment Services Locator-registered facility. The facility's programming is outpatient (Outpatient, MAT), not residential. Evaluation of this facility against current clinical standards should encompass ASAM 4e framework alignment, MAT policy, and payer-specific network status.

Care levels at Clinic 1 Methadone Clinic

Level-of-care documentation: Clinic 1 Methadone Clinic is an outpatient-focused program (Outpatient, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Under MHPAEA 2024 medical-necessity criteria disclosure, plan-specific criteria for each of these levels must be available to patients upon request. Mismatch between documented clinical need and offered level of care is a common source of authorization denial.

Insurance and payment

Clinic 1 Methadone Clinic accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The operational prerequisite for admission is written documentation of: (a) network contract status; (b) prior authorization; (c) cost-sharing structure; (d) medical-necessity criteria applied. Absence of any of these four increases the probability of post-admission financial disagreement.

Specialty programming

The facility's documented specialty programming includes: Young adults, Adult women, Pregnant/postpartum women. Evaluation of specialty-program alignment requires documented review of clinical team credentials, specialty-specific programming hours, and integrated assessment protocols. Specialty designation without documented clinical infrastructure is a recognized marketing pattern in the sector.

Before you call

Pre-admission due-diligence for Clinic 1 Methadone Clinic: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via NY behavioral-health regulator inspection records. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.